<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04958785</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-586-6144</org_study_id>
    <secondary_id>2021-001074-27</secondary_id>
    <nct_id>NCT04958785</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Adults With Metastatic Triple-Negative Breast Cancer</brief_title>
  <official_title>A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Nab-Paclitaxel or Paclitaxel Versus Nab-Paclitaxel or Paclitaxel in Previously Untreated Patients With Metastatic Triple-Negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study for the Safety Run-In Cohort is to evaluate the safety,&#xD;
      tolerability, and recommended Phase 2 dose (RP2D) of magrolimab in combination with&#xD;
      nab-paclitaxel or paclitaxel in metastatic triple-negative breast cancer (mTNBC).&#xD;
&#xD;
      The primary objective of this study for the Randomized Cohorts is to evaluate the efficacy of&#xD;
      magrolimab in combination with nab-paclitaxel or paclitaxel in solid tumors as determined by&#xD;
      progression-free survival (PFS) by investigator assessment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">November 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Run-in Cohort: Percentage of Participants Experiencing Dose-Limiting Toxicities (DLTs), Adverse Events (AEs), and Laboratory Abnormalities According to National Cancer Institute (NCI) Common Terminology Criteria for AEs (CTCAE), Version 5.0</measure>
    <time_frame>First dose date up to 35 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Randomized Cohort: Progression Free Survival (PFS) as Determined by Investigator Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, as determined by investigator assessment per RECIST version 1.1, or death from any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: Objective Response Rate (ORR) as Determined by Investigator Assessment and Independent Central Review</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>ORR is defined as the percentage of participants who achieve a complete response (CR) or partial response (PR), as measured by RECIST version 1.1, as determined by investigator assessment and independent central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: PFS as Determined by Independent Central Review Using RECIST Version 1.1</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>PFS is defined as the time from the date of randomization until the earliest date of documented disease progression, as determined by independent central review per RECIST version 1.1, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: Duration of Response (DOR) as Determined by Investigator Assessment per RECIST Version 1.1</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>DOR is defined as time from first documentation of complete response or partial response to the earliest date of documented disease progression, as determined by investigator assessment per RECIST version 1.1, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: Duration of Response (DOR) as Determined by Independent Central Review per RECIST Version 1.1</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>DOR is defined as time from first documentation of complete response or partial response to the earliest date of documented disease progression, as determined by independent central review per RECIST version 1.1, or death from any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Randomized Cohort: Overall Survival (OS)</measure>
    <time_frame>Up to 35 months</time_frame>
    <description>OS is defined as time from date of randomization to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in and Randomized Cohorts: Magrolimab Concentration Versus Time</measure>
    <time_frame>Up to end of treatment (approximately 35 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in and Randomized Cohorts: Antidrug Antibodies (ADA) to Magrolimab</measure>
    <time_frame>Up to end of treatment (approximately 35 months)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Triple-Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Run-in Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with untreated unresectable, locally advanced or metastatic TNBC whose tumors are not appropriate for immune checkpoint inhibitor therapy will receive the following:&#xD;
magrolimab in de-escalating doses to establish RP2D&#xD;
nab-paclitaxel 100 milligrams per square meter (mg/m^2) on Days 1, 8 and 15 of each cycle or paclitaxel 90 mg/m^2 on Days 1, 8 and 15 of each cycle per investigator choice. Each cycle is 28 days.&#xD;
Participants will continue treatment until no more than 2 of 6 dose limiting toxicity (DLT)-evaluable participants experience a DLT in Cycle 1, and will not change their magrolimab dose level after the RP2D is determined.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with mTNBC will receive the RP2D determined in the Safety Run-in cohort of magrolimab in combination with the nab-paclitaxel 100 mg/m^2 on Days 1, 8 and 15 of each cycle or paclitaxel 90 mg/m^2 on Days 1, 8 and 15 of each cycle per investigator choice. Each cycle is 28 days.&#xD;
Magrolimab will be continued until development of unacceptable toxicity that cannot be clinically managed by dose or schedule modifications. Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Randomized Cohort: Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with mTNBC will receive the nab-paclitaxel 100 mg/m^2 on Days 1, 8 and 15 of each cycle or paclitaxel 90 mg/m^2 on Days 1, 8 and 15 of each cycle per investigator choice. Each cycle is 28 days.&#xD;
Nab-paclitaxel or paclitaxel will be continued until development of unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Magrolimab</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Randomized Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Safety Run-in Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <other_name>GS-4721</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-Paclitaxel</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Randomized Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Randomized Cohort: Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Safety Run-in Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Administered intravenously</description>
    <arm_group_label>Randomized Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Randomized Cohort: Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <arm_group_label>Safety Run-in Cohort: Magrolimab + Nab-Paclitaxel or Paclitaxel</arm_group_label>
    <other_name>TaxolÂ®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Individual has provided informed consent&#xD;
&#xD;
          -  Individual is willing and able to comply with clinic visits and procedures outlined in&#xD;
             the study protocol&#xD;
&#xD;
          -  Individuals must have an Eastern Cooperative Oncology Group (ECOG) performance status&#xD;
             of 0 or 1&#xD;
&#xD;
          -  Laboratory measurements, blood counts: Adequate hemoglobin, neutrophil, and platelet&#xD;
             counts&#xD;
&#xD;
          -  Laboratory measurements, renal function: Adequate creatinine and liver function tests&#xD;
&#xD;
          -  Male and female individuals of childbearing potential who engage in heterosexual&#xD;
             intercourse must agree to use protocol-specified method(s) of contraception&#xD;
&#xD;
          -  Measurable disease according to RECIST, version 1.1. Previously irradiated lesions can&#xD;
             be considered as measurable disease only if disease progression has been unequivocally&#xD;
             documented at that site since radiation&#xD;
&#xD;
          -  Individuals must be willing to provide baseline tumor tissue from a core or excisional&#xD;
             biopsy (fine needle aspirate is not adequate). A newly obtained biopsy (within 90 days&#xD;
             prior to study treatment start) is strongly preferred, but an archival sample (within&#xD;
             6 months prior to study treatment start) is acceptable. Individuals will also be&#xD;
             requested to consent to a mandatory on-treatment tumor biopsy unless not feasible as&#xD;
             determined by the investigator and discussed with the sponsor&#xD;
&#xD;
          -  Individuals previously untreated for unresectable locally advanced or mTNBC that is&#xD;
             histologically or cytologically confirmed based on the most recent analyzed biopsy or&#xD;
             other pathology specimen, as defined by the most recent American Society of Clinical&#xD;
             Oncology/College of American Pathologists (ASCO/CAP) guideline&#xD;
&#xD;
          -  Individuals whose tumors do not express programmed cell death ligand 1 (PD-L1), as&#xD;
             determined by an approved test according to local regulations&#xD;
&#xD;
          -  Prior systemic treatment for neoadjuvant and/or adjuvant therapy and/or curative&#xD;
             intent radiation therapy is permitted if completed at least 6 months prior to&#xD;
             enrollment.&#xD;
&#xD;
        Note: Maintenance therapies are not counted as separate lines of therapy.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Positive serum pregnancy test&#xD;
&#xD;
          -  Breastfeeding female&#xD;
&#xD;
          -  Active central nervous system (CNS) disease. Individuals with asymptomatic and stable,&#xD;
             treated CNS lesions (radiation and/or surgery and/or other CNS-directed therapy who&#xD;
             have not received corticosteroids for at least 4 weeks) are allowed&#xD;
&#xD;
          -  Red blood cell (RBC) transfusion dependence, defined as requiring more than 2 units of&#xD;
             packed RBC transfusions during the 4-week period prior to screening. RBC transfusions&#xD;
             are permitted during the screening period and prior to enrollment to meet the&#xD;
             hemoglobin inclusion criteria&#xD;
&#xD;
          -  History of hemolytic anemia, autoimmune thrombocytopenia, or Evans syndrome in the&#xD;
             last 3 months&#xD;
&#xD;
          -  Known hypersensitivity to any of the study drugs, the metabolites, or formulation&#xD;
             excipient&#xD;
&#xD;
          -  Prior treatment with cluster of differentiation 47 (CD47) or signal regulatory protein&#xD;
             alpha-targeting agents&#xD;
&#xD;
          -  Current participation in another interventional clinical trial&#xD;
&#xD;
          -  Known inherited or acquired bleeding disorders&#xD;
&#xD;
          -  Significant disease or medical conditions, as assessed by the investigator and&#xD;
             sponsor, that would substantially increase the risk-benefit ratio of participating in&#xD;
             the study&#xD;
&#xD;
          -  Known active or chronic hepatitis B or C infection or human immunodeficiency virus&#xD;
             infection in medical history)&#xD;
&#xD;
          -  Prior anticancer therapy including but not limited to chemotherapy, immunotherapy, or&#xD;
             investigational agents within 4 weeks prior to magrolimab is not permitted.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gilead Clinical Study Information Center</last_name>
    <phone>1-833-445-3230 (GILEAD-0)</phone>
    <email>GileadClinicalTrials@gilead.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Astera Cancer Care</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bruno Fang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 1, 2021</study_first_submitted>
  <study_first_submitted_qc>July 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Magrolimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

